From Atlanta, at a meeting of the American Society of Hematology
A team of researchers has plucked the first fruit of what the group’s leader calls a “new approach to drug discovery.” Scott A.
Armstrong of Children’s Hospital and the Dana-Farber Cancer Institute in Boston and his colleagues found that the drug rapamycin, in combination with standard chemotherapy for acute lymphoblastic leukemia (ALL), can kill chemotherapy-resistant cells.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.